I-Mab s Announcement on Unusual Price Movement SHANGHAI, China, and GAITHERSBURG, MD. I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercia

I-Mab s Announcement on Unusual Price Movement

SHANGHAI, China, and GAITHERSBURG, MD. I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage

biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics. The Company has noted the recent unusual fluctuations in the price and trading volume of the American depositary shares (the

ADSs ) of the Company and emphasizes that its business and pipeline developments are all well on track and have no adverse changes. The Company has strong confidence in its global competitive pipeline and is accelerating ongoing

transformation towards an integrated global biopharma as planned.

Latest Development of Lemzoparlimab and Uliledlimab:

The Company s fundamentals remain very strong. In 2021, I-Mab has successfully delivered planned important

clinical and corporate milestones and will continue building on the strong momentum to deliver critical new milestones, including reporting multiple key clinical data readouts, initiating new registrational trials and accelerating dual listing on

The Main Board of The Stock Exchange of Hong Kong Limited, continually creating value for patients and shareholders.

I-Mab (Nasdaq: IMAB) is an innovation-driven global biopharma company focused on the discovery, development and commercialization of novel and highly differentiated biologics for immuno-oncology and autoimmune

diseases. The Company s mission is to bring transformational medicines to patients around the world through innovation. I-Mab s globally competitive pipeline of more than 20 clinical and

preclinical-stage drug candidates is driven by its internal discovery and global partnerships for in-licensing, based on the Company s Fast-to-Proof-of-Concept and Fast-to-Market development strategies. The Company

is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability.

I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please

visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Forward Looking Statements

This press release includes certain disclosures which contain forward-looking statements. You can identify forward-looking statements because they

contain words such as anticipate and expected. Forward-looking statements are based on I-Mab s current expectations and assumptions. Because forward-looking statements relate to

the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or

assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in filings with the U.S. Securities and Exchange Commission. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.